Key result
Higher baseline plasma concentrations of ANGPT2 were significantly associated with an increased risk of progression to ESKD or a 40% decline in eGFR (HR 2.09).
Why the study?
Prognostic biomarkers reflective of underlying molecular mechanisms are critically needed for effective management of diabetic kidney disease.
Does plasma ANGPT2 level predict the progression to ESKD or 40% eGFR decline in patients with diabetic kidney disease?
Population
Patients with diabetic kidney disease across discovery (N=58), validation (N=68), and independent (N=210) cohorts
Comparison
Three-marker plasma proteomic panel added to clinical parameters vs clinical parameters alone
Design
Cohort study with multi-scalar data integration and transcriptomics
Authors
Loading...
May refine DKD progression risk stratification; leaves open incremental value and therapeutic targeting of ANG-TIE signaling.
Cohort (n=336)
Yes
Does plasma ANGPT2 level predict the progression to ESKD or 40% eGFR decline in patients with diabetic kidney disease?
Hazard Ratio: 2.09 (95% CI 1.4–3.12)
Plasma ANGPT2 is a prognostic biomarker for diabetic kidney disease progression that reflects underlying glomerular ANG-TIE signaling activation.
Liu et al. (2021) conducted a cohort in Diabetic kidney disease (n=336). Plasma angiopoietin 2 (ANGPT2) levels vs. Lower ANGPT2 levels was evaluated on End-stage kidney disease (ESKD) or more than 40% reduction from baseline eGFR (HR 2.09, 95% CI 1.40-3.12). Higher baseline plasma concentrations of ANGPT2 were significantly associated with an increased risk of progression to ESKD or a 40% decline in eGFR (HR 2.09).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: